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In the last 15 years, the practice guidelines as well as the
real-world clinical care of patients with atrial fibrilla-
tion (AF), in particular the management of thrombo-
embolic risk, has evolved and deeply changed.1
Nowadays, all the current international guidelines rec-
ommend unanimously that AF patients need to be trea-
ted with oral anticoagulant (OAC) drugs, with the only
exception of patients at low thromboembolic risk.2
Among the available OAC drugs, again the guidelines
uniformly indicate the non-vitamin K antagonist OACs
(NOACs) as the preferred treatment compared with
vitamin K antagonists (VKAs), on the basis of evidence
indicating a similar (even superior) effectiveness and a
safer clinical profile.2 Recent epidemiological evidence
confirmed that on these premises the overall rate of
OAC prescription has significantly increased in the
recent years.3
Notwithstanding the clear indications coming from
the guidelines, a high baseline bleeding risk is com-
monly considered as a major contraindication to with-
hold OAC prescription.4 This practice may occur
despite the fact that all the guidelines agree that a
high bleeding risk at baseline evaluation is not a suffi-
cient reason for avoiding prescription of OAC.2 Rather
than doing this, a high bleeding risk should be a reason
to flag patients that should receive specific interventions
in order to control and modulate all the modifiable and
potentially modifiable bleeding risk factors.2
In the study presented by Gamble et al., published in
the European Journal of Preventive Cardiology, which
focused on a cohort of AF patients experiencing a
stroke event, the majority of patients (64%) reported
both a high thromboembolic risk (based on CHA2DS2-
VASc score) and a high bleeding risk (based on a
modified version of the HEMORR2HAGES score).
5
The authors analyzed the prescription of OAC prior
to stroke occurrence and found that only two thirds
of patients with high thromboembolic and bleeding
risks were treated with OAC before the occurrence of
event. Moreover, they analyzed the impact of previous
OAC treatment on both in-hospital and long-term
mortality.5 They found that those patients with high
thromboembolic and bleeding risks that were on treat-
ment with OAC prior to the stroke occurrence had a
significantly lower risk for both in-hospital (30% risk
reduction) and long-term mortality (20% risk reduc-
tion), after full multivariate adjustment.5
While we should not be surprised that those patients
with a high thromboembolic risk reported a contem-
porary high bleeding risk, in consideration of the simi-
larity in terms of risk factors recognized for both
conditions, the reported data regarding the reduced
mortality risk are extremely interesting. The evidence
that even in high-risk patients, such as those that had
already reported a stroke event, the prescription of
OAC in patients with a high bleeding risk may grant
a significant reduction in short- and long-term mortal-
ity risk underlines and substantiates the guidelines’
recommendations on properly considering the data
regarding baseline risk evaluation and avoiding any
decision-making based on perceptions rather than
facts. On one hand, following the evaluation of
thromboembolic risk to guide prescription confirms
the significant role in reducing adverse outcomes of
great clinical value. On the other hand, notwithstand-
ing the high bleeding risk, the net clinical advantage of
OAC prescription appears to be substantial and
persistent.
Previous data have already confirmed that OAC pre-
scription according to the guidelines’ recommendations
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provide a significant reduction of major adverse events
in AF patients.6,7 Furthermore, the data presented con-
firm and reinforce the previous data, illustrating how
the appropriate prescription of OAC in AF patients is
associated with a significant reduction in mortality.8
Considering the previous evidence and the data pre-
sented by Gamble et al.,5 we can again confirm how the
evaluation of bleeding risk should not be the basis for
excluding OAC prescription; rather, we stress the clin-
ical value of using the so-called ‘Birmingham 3-Step’
management strategy.2 In this clinical management
proposal, while the evaluation of thromboembolic
risk is pivotal to identify patients to be treated with
OAC (Step 1), the evaluation of bleeding risk is neces-
sary to distinguish those that need to be more carefully
followed and for which specific strategies are needed to
reduce the risk of major bleeding events (Step 2).
Finally, careful evaluation is needed to choose
the more adequate OAC treatment according to
the patient’s specific characteristics (Step 3).2 This
approach should be further included in an integrated
model to manage AF patients in an holistic way, in
order to optimize the clinical management and reduce
the overall risk of adverse outcomes, such as the
recently proposed ‘Atrial Fibrillation Better Care’
(ABC) pathway2 (Figure 1), which aims to control for
all the relevant aspects that could contribute to redu-
cing the overall risk of adverse outcomes, as well as the
strict control of any contributing risk factors,9 such as
lifestyle10 or smoking habits.11
The appropriate use of clinical risk scores is neces-
sary to optimize the management of AF patients and to
propose to the patients’ their best options on the basis
of more informed evidence coming from clinical prac-
tice guidelines. The misuse of these tools should be
avoided, which includes delegating to the scores the
‘core’ of the clinical decision process, resulting in
‘score-related automatic decisions’. Conversely, the
value of risk prediction scores is undebatable as a reli-
able tool to help, and not replace, the complex process
of medical decision-making.
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